Phibro Animal Health Corporation (NASDAQ:PAHC) Given Average Recommendation of “Hold” by Brokerages

Phibro Animal Health Corporation (NASDAQ:PAHC) has received a consensus recommendation of “Hold” from the five ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $42.50.

PAHC has been the subject of several analyst reports. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st. Weiss Ratings cut shares of Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Wall Street Zen cut Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Citigroup dropped their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PAHC. Cetera Investment Advisers raised its position in shares of Phibro Animal Health by 2.7% in the first quarter. Cetera Investment Advisers now owns 10,997 shares of the company’s stock worth $608,000 after acquiring an additional 293 shares during the period. 1620 Investment Advisors Inc. raised its holdings in shares of Phibro Animal Health by 77.4% during the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after acquiring an additional 295 shares during the last quarter. Tudor Investment Corp ET AL raised its stake in Phibro Animal Health by 3.4% in the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after purchasing an additional 338 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Phibro Animal Health by 2.9% in the second quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after buying an additional 363 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after purchasing an additional 386 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Stock Up 0.9%

Shares of PAHC stock opened at $34.36 on Friday. The company’s fifty day moving average price is $33.34 and its 200-day moving average price is $42.76. Phibro Animal Health has a one year low of $28.25 and a one year high of $60.08. The company has a market capitalization of $1.39 billion, a price-to-earnings ratio of 14.75, a PEG ratio of 0.48 and a beta of 0.46. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, September 2nd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.4%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 20.60%.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.